Stockreport

Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular Carcinoma Trial

Inovio Pharmaceuticals, Inc.  (INO) 
NASDAQ:AMEX Investor Relations: ir.inovio.com/investors/default.aspx
PDF PLYMOUTH MEETING, Pa., Jan. 29, 2020 /PRNewswire/ -- Geneos Therapeutics announced today that its personalized neoantigen-targeting vaccine, GNOS-PV02 (based on its prop [Read more]